LCM
IMRX icon

Landscape Capital Management’s Immuneering IMRX Stock Holding History

Landscape Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Sell
67,495
-14,854
-18% -$76.1K 0.02% 548
2025
Q4 		$542K Buy
+82,349
New +$529K 0.04% 464

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Landscape Capital Management's IMRX Position: Q1 2026 in Review

Landscape Capital Management reduced its Immuneering (IMRX) stake by 18% in Q1 2026, selling an estimated $76.1K and leaving 67,495 shares worth $356K. The position accounts for 0.02% of the portfolio, ranked #548.

Landscape Capital Management first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $542K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Landscape Capital Management held 67,495 shares of Immuneering worth $356K as of Q1 2026.
  • Landscape Capital Management sold 14,854 Immuneering shares in Q1 2026, an estimated $76.1K.
  • Immuneering made up 0.02% of Landscape Capital Management's portfolio in Q1 2026, its #548 holding.
  • Landscape Capital Management first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • Landscape Capital Management's Immuneering position peaked at $542K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Landscape Capital Management's 13F filing for Q1 2026, filed 12 May 2026.